Skip to content

Study · Systematic review · 2015

5 results

Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis.

Sun F, Sun F, Wu S, Wang J, Guo S, Chai S, Yang Z, Li L, Zhang Y, Ji L, Zhan S

Clinical therapeutics29 Dec 2014Cited by 194 (Europe PMC)

PMID25554560 (opens in a new tab)DOI10.1016/j.clinthera.2014.11.008 (opens in a new tab)PepBankPUB-25554560
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found that liraglutide 1.8 mg once daily decreased total cholesterol versus placebo and thiazolidinediones.

    In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg once daily lowered total cholesterol compared with placebo and thiazolidinediones.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol
    Study

    n: not reported in source

    Comparator
    Placebo and thiazolidinediones
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.8 mg once dailyAs given in this study (human).

    Source sentences

    Summary
    Exenatide, liraglutide 1.8 mg once daily, and taspoglutide decreased total cholesterol with a range of -0.16 mmol/L (95% CI, -0.26 to -0.06) to -0.27 mmol/L (95% CI, -0.41 to -0.12) versus placebo and thiazolidinediones (range, -0.26 to -0.37 mmol/L).
    1 context sentence
    Summary · context
    Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, the decrease in total cholesterol was more evident with exenatide long-acting release and liraglutide 1.8 mg once daily.

    In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg once daily lowered total cholesterol, with a more evident drop than some other GLP-1 drugs.

    Peptide
    Liraglutide
    Outcome
    DecreaseTotal cholesterol, liraglutide 1.8 mg
    Study

    n: not reported in source

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.8 mg once dailyAs given in this study (human).

    Source sentences

    Summary
    The decreased effect was more evident in exenatide long-acting release and liraglutide 1.8 mg once daily.
    1 context sentence
    Summary · context
    Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, liraglutide 1.8 mg once daily significantly reduced triglycerides versus placebo.

    In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg once daily lowered triglycerides compared with placebo.

    Peptide
    Liraglutide
    Outcome
    DecreaseTriglycerides, liraglutide 1.8 mg
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Lipids · Cardiovascular
    Studied dose
    1.8 mg once dailyAs given in this study (human).

    Measurements

    Triglyceride change
    −0.3 mmol/L
    liraglutide 1.8 mg once daily vs placebo

    Source sentences

    Summary
    A significant reduction in triglyceride levels was observed with liraglutide 1.8 mg once daily (-0.30 mmol/L [95% CI, -0.49 to -0.11])
    1 context sentence
    Summary · context
    Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists decreased HDL-C compared with thiazolidinediones.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class lowered HDL cholesterol compared with thiazolidinediones.

    Peptide
    Liraglutide
    Outcome
    DecreaseHDL-C
    Study

    n: not reported in source

    Comparator
    Thiazolidinediones
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    GLP-1 RAs decreased HDL-C with a range of -0.06 mmol/L (95% CI, -0.11 to -0.01) to -0.13 mmol/L (95% CI, -0.17 to -0.10) compared with thiazolidinediones
    1 context sentence
    Summary · context
    Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, all GLP-1 receptor agonists pooled significantly reduced LDL-C versus placebo, insulin and thiazolidinediones.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a class lowered LDL cholesterol compared with placebo, insulin and thiazolidinediones.

    Peptide
    Liraglutide
    Outcome
    DecreaseLDL-C
    Study

    n: not reported in source

    Comparator
    Placebo, insulin and thiazolidinediones
    Outcome group
    Lipids · Cardiovascular

    Source sentences

    Summary
    A significant reduction in LDL-C was detected for all GLP-1 RAs versus placebo (range, -0.08 to -0.16 mmol/L), insulin (range, -0.10 to -0.19 mmol/L), and thiazolidinediones (range, -0.16 to -0.24 mmol/L).
    1 context sentence
    Summary · context
    Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.